ARWR
Arrowhead Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$86.34
−0.17%Aug 30, 2026, 15:30 UTC
Arrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran at the ESC Congress 2026 in Munich, showing reduced acute pancreatitis events in patients with severe hypertriglyceridemia.
Aug 24, 2026, 11:30 UTC
Arrowhead Pharmaceuticals announced it will present new clinical data for plozasiran at the European Society of Cardiology Congress in Munich, Germany, on August 30, 2026.
Source:Aug 5, 2026, 00:40 UTC
Arrowhead Pharmaceuticals held its Q3 2026 earnings call on August 4, 2026.
Source:Aug 4, 2026, 22:04 UTC
Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia and is accelerating plans for a supplemental New Drug Application.
Source:Aug 4, 2026, 20:01 UTC
Arrowhead Pharmaceuticals signed an agreement to acquire an FDA Rare Pediatric Disease Priority Review Voucher from an undisclosed third party.
Source:Jul 22, 2026, 18:25 UTC
Arrowhead Pharmaceuticals announced successful topline results from its late-stage SHASTA-3 and SHASTA-4 trials of plozasiran for severe hypertriglyceridemia.
Jun 22, 2026, 16:33 UTC
Arrowhead Pharmaceuticals received marketing authorization from the European Union for REDEMPLO (plozasiran) to treat adults with familial chylomicronemia syndrome.
Jun 16, 2026, 00:00 UTC
Dr. Matt Cohen was appointed as a director of Arrowhead Pharmaceuticals, Inc., effective June 12, 2026.